Datopotamab Deruxtecan Improves Survival in Triple-Negative Breast Cancer
Rebecca Dent, MD, National Cancer Centre Singapore, Singapore, discusses results from the phase 3 TROPION-Breast02 trial evaluating datopotamab deruxtecan (Dato-DXd) versus investigator’s choice chemotherapy in patients with metastatic triple-negative breast cancer (TNBC).
Results demonstrate that Dato-DXd significantly improved progression-free survival, overall survival, and duration of response with a manageable and consistent safety profile. This benefit was also seen in patients with early relapse and stable brain metastases. This data establishes Dato-DXd as a potential new standard of care in the first-line treatment of metastatic TNBC.
These results were presented at the the 2025 European Society for Medical Oncology (ESMO) Annual Meeting in Berlin, Germany.
Source:
Dent R, Shao Z, Schmid P, et al. Datopotamab deruxtecan (Dato-DXd) vs chemotherapy (CT) in patients (pts) with locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC) who are not candidates for PD-(L)1 inhibitor therapy: Primary results from the randomised, phase 3 TROPION-Breast02 trial. Presented at the 2025 ESMO Congress. October 17-21, 2025; Berlin, Germany. LBA21
